Changes of PC and AT-III in the patients with II diabetic nephropathy
Tong Feng-zh
Abstract
Tong Feng-zh
Abstract
Objective To investigate the changes of serum Protein C (PC) and Antithrombin Ⅲ (AT-Ⅲ) in the early or late stage of the patients with diabetic nephropathy (DN) and explore the effect of PC and AT-Ⅲ in etiopathology and progression of DN. Methods The serum samples were collected from 125 Ⅱ diabetes mellitus (DM) patients and 38 controls, and the DM group was divided into non-albuminuria group (UAE30mg/24h, 45 samples) and albuminuria group (UAE30mmg/24h, 80 samples). Then, the level of PC and the activity of AT-Ⅲ were detected, respectively. Results Compared with controls (102.3±17.3%), the level of PC in both non-albuminuria group and albuminuria group significantly increased (non-albuminuria group: 124.1±10.7%, p 0.05; albuminuria group: 171.5±36.5%, p 0.05). In addition, the level of PC in the albuminuria group was significantly higher than that in the non-albuminuria group (p0.05). Compared with controls (95.4±6.5%), the activityl of AT-Ⅲ in both non-albuminuria group and albuminuria group significantly decreased (non-albuminuria group:79.4±29.4%, p 0.05); albuminuria group: 40.6± 13.2%(p 0.05). In addition, the acticvity of AT-Ⅲ in the albuminuria group was significantly lower than that in the non-albuminuria group (p 0.05). Conclusions It is obvious that DM patients have coagulation disorder and the degree of the disorder relates with the development of DM. PC and AT-Ⅲ can be used in monitoring the progression of DN, especially in the early stage.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To investigate the changes of serum Protein C (PC) and Antithrombin Ⅲ (AT-Ⅲ) in the early or late stage of the patients with diabetic nephropathy (DN) and explore the effect of PC and AT-Ⅲ in etiopathology and progression of DN. Methods The serum samples were collected from 125 Ⅱ diabetes mellitus (DM) patients and 38 controls, and the DM group was divided into non-albuminuria group (UAE30mg/24h, 45 samples) and albuminuria group (UAE30mmg/24h, 80 samples). Then, the level of PC and the activity of AT-Ⅲ were detected, respectively. Results Compared with controls (102.3±17.3%), the level of PC in both non-albuminuria group and albuminuria group significantly increased (non-albuminuria group: 124.1±10.7%, p 0.05; albuminuria group: 171.5±36.5%, p 0.05). In addition, the level of PC in the albuminuria group was significantly higher than that in the non-albuminuria group (p0.05). Compared with controls (95.4±6.5%), the activityl of AT-Ⅲ in both non-albuminuria group and albuminuria group significantly decreased (non-albuminuria group:79.4±29.4%, p 0.05); albuminuria group: 40.6± 13.2%(p 0.05). In addition, the acticvity of AT-Ⅲ in the albuminuria group was significantly lower than that in the non-albuminuria group (p 0.05). Conclusions It is obvious that DM patients have coagulation disorder and the degree of the disorder relates with the development of DM. PC and AT-Ⅲ can be used in monitoring the progression of DN, especially in the early stage.
Key concepts: Albuminuria, Medicine, Diabetic nephropathy, Diabetes mellitus, Internal medicine, Urology, Endocrinology, Nephropathy